ASCO 2016: Phase I Trial Results With Vorinostat in Head and Neck Cancer
In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
In this interview, Theodoros Teknos, MD, a Professor at The Ohio State University Medical School and Chairman for the Department of Otolaryngology (Head & Neck Surgery) at the Ohio State University Medical Center /James Cancer Hospital, sat down with the OncoTherapy Network to discuss the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
These results were also presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7, 2016, in Chicago (abstract 6036).
Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy
April 28th 2024Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.
Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer
March 5th 2024Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.
